Trabectedin for the treatment of breast cancer

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Expert Opinion on Investigational Drugs

• Publication date

  2016-01-02

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/13543784.2016.1124086PMID 26592307
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial.

  2015cited by this paper
• Anti-programmed cell death protein-1/ligand-1 therapy in different cancers

  2015cited by this paper
• A phase IIb multicentre study comparing the efficacy of trabectedin to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma: the TRUSTS trial.

  2015cited by this paper
• Phase I study of the safety and pharmacokinetics of trabectedin with docetaxel in patients with advanced malignancies

  2015cited by this paper
• Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial.

  2015cited by this paper
• Abstract S1-09: A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer

  2015cited by this paper
• Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.

  2015cited by this paper
• Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study.

  2015cited by this paper
• Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study.

  2015cited by this paper
• Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199.

  2014influential reference
• The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis

  2014cited by this paper
• Activity of trabectedin in germline BRCA1/2-mutated metastatic breast cancer: results of an international first-in-class phase II study.

  2014cited by this paper
• Trabectedin, a drug acting on both cancer cells and the tumour microenvironment

  2014cited by this paper
• Resistance to minor groove binders.

  2014cited by this paper
• Abstract 1686: Synergistic combination of Trabectedin and Olaparib in breast cancer tumor cell lines

  2014cited by this paper
• Trabectedin as a single-agent treatment of advanced breast cancer after anthracycline and taxane treatment: a multicenter, randomized, phase II study comparing 2 administration regimens.

  2014cited by this paper
• Anti-angiogenic effects of trabectedin (Yondelis; ET-743) on human breast cancer cells

  2014cited by this paper
• Trabectedin and indole-3-carbinol combination in heavily pretreated metastatic breast cancer: Results of a pilot clinical study.

  2014cited by this paper
• Mode of action of trabectedin in myxoid liposarcomas

  2014cited by this paper
• Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.

  2014influential reference
• Antiangiogenic activity of trabectedin in myxoid liposarcoma: Involvement of host TIMP‐1 and TIMP‐2 and tumor thrombospondin‐1

  2014cited by this paper
• Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients

  2014cited by this paper
• Role of macrophage targeting in the antitumor activity of trabectedin.

  2013cited by this paper
• New activities for the anti-tumor agent trabectedin: taking two birds with one stone

  2013cited by this paper
• A diverse induction of apoptosis by trabectedin in MCF-7 (HER2-/ER+) and MDA-MB-453 (HER2+/ER-) breast cancer cells.

  2013cited by this paper
• Analysis of DNA Repair–Related Genes in Breast Cancer Reveals CUL4A Ubiquitin Ligase as a Novel Biomarker of Trabectedin Response

  2013cited by this paper
• A phase II trial of trabectedin (T) in patients with hormone receptor-positive, HER2-negative advanced breast cancer, according to xeroderma pigmentosum gene (XPG) expression.

  2012cited by this paper
• Characterization of a new trabectedin‐resistant myxoid liposarcoma cell line that shows collateral sensitivity to methylating agents

  2012cited by this paper
• Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone

  2012cited by this paper
• A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials

  2012influential reference
• A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: a gynecologic oncology group study.

  2012cited by this paper
• Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors

  2012cited by this paper
• Phase I combination study of trabectedin and capecitabine in patients with advanced malignancies

  2012cited by this paper
• Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma.

  2012cited by this paper
• Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum.

  2012cited by this paper
• Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer.

  2012cited by this paper
• Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimens: a phase II study of the Gynecologic Oncology Group.

  2011cited by this paper
• XPF-dependent DNA breaks and RNA polymerase II arrest induced by antitumor DNA interstrand crosslinking-mimetic alkaloids.

  2011cited by this paper
• Phase I and Pharmacokinetic Study of Sequential Paclitaxel and Trabectedin Every 2 Weeks in Patients with Advanced Solid Tumors

  2010cited by this paper
• Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells.

  2010cited by this paper
• A Review of Trabectedin (ET-743): A Unique Mechanism of Action

  2010cited by this paper
• Phase I and Pharmacokinetic Study of Trabectedin as a 1- or 3-hour Infusion Weekly in Patients with Advanced Solid Malignancies

  2009cited by this paper
• Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules.

  2009cited by this paper
• Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours.

  2009cited by this paper
• Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors

  2009cited by this paper
• Single-agent trabectedin as second-line therapy of persistent or recurrent endometrial cancer: results of a multicenter phase II study.

  2009cited by this paper
• Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer.

  2009cited by this paper
• Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer.

  2009cited by this paper
• Role of homologous recombination in trabectedin-induced DNA damage.

  2008cited by this paper
• Von Hippel-Lindau–Coupled and Transcription-Coupled Nucleotide Excision Repair–Dependent Degradation of RNA Polymerase II in Response to Trabectedin

  2008cited by this paper
• A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies.

  2008cited by this paper
• Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors

  2008cited by this paper
• Dynamics of cell cycle phase perturbations by trabectedin (ET‐743) in nucleotide excision repair (NER)‐deficient and NER‐proficient cells, unravelled by a novel mathematical simulation approach

  2007cited by this paper
• The apoptosome: signalling platform of cell death

  2007cited by this paper
• Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743

  2007cited by this paper
• A phase II study of Yondelis® (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer

  2006cited by this paper
• Selective Effects of the Anticancer Drug Yondelis (ET-743) on Cell-Cycle Promoters

  2005cited by this paper
• Hallmarks of 'BRCAness' in sporadic cancers

  2004cited by this paper
• Dietary agent indole‐3‐carbinol protects female rats against the hepatotoxicity of the antitumor drug ET‐743 (trabectidin) without compromising efficacy in a rat mammary carcinoma

  2004cited by this paper
• Apoptosis pathways in cancer and cancer therapy

  2004cited by this paper
• Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours.

  2003cited by this paper
• A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies.

  2002cited by this paper
• Sequence-dependent synergistic cytotoxicity of ecteinascidin-743 and paclitaxel in human breast cancer cell lines in vitro and in vivo.

  2002cited by this paper
• Differential Cytostatic and Apoptotic Effects of Ecteinascidin-743 in Cancer Cells

  2002cited by this paper
• Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair

  2001cited by this paper
• Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors.

  2001cited by this paper
• Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies.

  2001cited by this paper
• Unique pattern of ET‐743 activity in different cellular systems with defined deficiencies in DNA‐repair pathways

  2001cited by this paper
• Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action.

  2001cited by this paper
• Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation.

  2000cited by this paper
• Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study.

  2000cited by this paper
• Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer.

  1999cited by this paper
• In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients.

  1998cited by this paper
• PROGRESS IN THE ACQUISITION OF NEW MARINE-DERIVED ANTICANCER COMPOUNDS : DEVELOPMENT OF ECTEINASCIDIN-743 (ET-743)

  1996cited by this paper

• The DNA Minor Groove Binders Trabectedin and Lurbinectedin Are Potent Antitumor Agents in Human Intrahepatic Cholangiocarcinoma

  2025cites this paper
• Marine natural products as an important source of bioactive substances for non-alcoholic fatty liver disease management

  2025cites this paper
• Targeting tumor-associated macrophages: Critical players in tumor progression and therapeutic strategies (Review)

  2024cites this paper
• Trabectedin and Lurbinectedin Modulate the Interplay between Cells in the Tumour Microenvironment—Progresses in Their Use in Combined Cancer Therapy

  2024cites this paper
• Interactions between tumor-associated macrophages and regulated cell death: therapeutic implications in immuno-oncology

  2024cites this paper
• Immunometabolic actions of trabectedin and lurbinectedin on human macrophages: relevance for their anti-tumor activity

  2023cites this paper
• Tumor-associated macrophages: new insights on their metabolic regulation and their influence in cancer immunotherapy

  2023cites this paper
• Drug Repositioning Based on the Enhanced Message Passing and Hypergraph Convolutional Networks

  2022cites this paper
• From seaside to bedside: Current evidence and future perspectives in the treatment of breast cancer using marine compounds

  2022cites this paper
• Trabectedin suppresses escape from therapy-induced senescence in tumor cells by interfering with glutamine metabolism.

  2022cites this paper
• Phosphoinositide 3-kinase/Akt and its related signaling pathways in the regulation of tumor-associated macrophages polarization

  2022cites this paper
• Tumor-Associated Macrophages as Treatment Target in Colorectal Cancer

  2022cites this paper
• MS4A1 as a Potential Independent Prognostic Factor of Breast Cancer Related to Lipid Metabolism and Immune Microenvironment Based on TCGA Database Analysis

  2021cites this paper
• The Tumor Microenvironment in SCC: Mechanisms and Therapeutic Opportunities

  2021cites this paper
• Inflammation and tumor progression: signaling pathways and targeted intervention

  2021cites this paper
• Tumor-Associated Macrophages: A Potential Target for Cancer Therapy

  2021cites this paper
• Targeting tumor-associated macrophages as an antitumor strategy.

  2020cites this paper
• Trabectedin (Yondelis®) as a Therapeutic Option in Gynecological Cancers: A Focus on its Mechanisms of Action, Clinical Activity, and Genomic Predictors of Drug Response.

  2020cites this paper
• CUL4A, ERCC5, and ERCC1 as Predictive Factors for Trabectedin Efficacy in Advanced Soft Tissue Sarcomas (STS): A Spanish Group for Sarcoma Research (GEIS) Study

  2020cites this paper
• Targeting the intrinsically disordered architectural High Mobility Group A (HMGA) oncoproteins in breast cancer: learning from the past to design future strategies

  2020cites this paper
• Breast Cancer and Immunosenescence

  2019cites this paper
• Genomic Characteristics of Triple-Negative Breast Cancer Nominate Molecular Subtypes That Predict Chemotherapy Response

  2019cites this paper
• Next Generation Immunotherapy for Pancreatic Cancer: DNA Vaccination is Seeking New Combo Partners

  2018cites this paper
• Macrophage polarization as a novel weapon in conditioning tumor microenvironment for bladder cancer: can we turn demons into gods?

  2018cites this paper
• Depletion of tumor-associated macrophages switches the epigenetic profile of pancreatic cancer infiltrating T cells and restores their anti-tumor phenotype

  2018cites this paper
• Trabectedin modulates the senescence-associated secretory phenotype and promotes cell death in senescent tumor cells by targeting NF-κB

  2018cites this paper
• A drug development perspective on targeting tumor‐associated myeloid cells

  2018cites this paper
• MEK inhibitors cobimetinib and trametinib, regressed a gemcitabine-resistant pancreatic-cancer patient-derived orthotopic xenograft (PDOX)

  2017cites this paper
• Reprogramming of Tumor-Associated Macrophages with Anticancer Therapies: Radiotherapy versus Chemo- and Immunotherapies

  2017cites this paper
• Nanomedicine Strategies to Target Tumor-Associated Macrophages

  2017cites this paper
• A phase II trial of trabectedin in triple-negative and HER2-overexpressing metastatic breast cancer

  2016influential citation
• Pharmacodynamic Modeling of Cell Cycle Effects for Gemcitabine and Trabectedin Combinations in Pancreatic Cancer Cells

  2016cites this paper
• Trabectedin as a chemotherapy option for patients with BRCA deficiency.

  2016cites this paper